search
Back to results

Efficacy and Tolerability of Topiramate in Treatment of Bipolar Mania and Alcohol Use in Adolescents and Young Adults

Primary Purpose

Bipolar Disorder, Alcohol Abuse

Status
Completed
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
quetiapine and placebo
Quetiapine and Topiramate
Sponsored by
University of Cincinnati
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Bipolar Disorder focused on measuring Adolescents

Eligibility Criteria

12 Years - 25 Years (Child, Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Ages 12-25 years;
  2. DSM-IV-TR83 criteria for bipolar disorder, type I, manic or mixed episode;
  3. Young Mania Rating Scale (YMRS)86-88 score of > 16 at screening and baseline visits;
  4. DSM-IV-TR83 criteria for current alcohol abuse or dependence;
  5. Drinking >8 drinks in 30 days within the previous 6 months while meeting DSM-IV criteria for alcohol abuse or dependence.

    One standard drink is defined as 0.35 liters of beer, 0.15 liters of wine, or 0.04 liters of 80-proof liquor;

  6. Fluent in English;
  7. Provision of written informed consent/assent; 8) If female and of child bearing potential, agrees to use one of the following method of birth control: complete abstinence, barrier (diaphragm or condom), or oral contraceptive containing > 35 micrograms of ethinyl estradiol (because concomitant use of topiramate and lower estrogen oral contraceptives may lead to contraceptive failure).

Exclusion Criteria:

  1. Manic symptoms resulting from acute medical illness or acute intoxication or withdrawal from drugs or alcohol as determined by medical evaluation and rapid symptom resolution;
  2. Clinically significant alcohol or drug withdrawal symptoms that have the potential to cause serious consequences as determined by vital signs, the CIWA-Ar,84 and medical evaluation;
  3. Any unstable medical illness or laboratory abnormalities > 3 times upper limits of normal;
  4. A documented history of mental retardation or an IQ total score < 70 as determined by the Wechsler Abbreviated Scale of Intelligence (WASI),154 administered by a trained psychometrician;
  5. Any substance use other than alcohol, nicotine, or cannabis during the 30 days prior to study participation;
  6. A positive urine pregnancy test or lactating;
  7. History of nephrolithiasis.
  8. Treatment with concurrent mood stabilizers, antipsychotics or antidepressants;
  9. Treatment with antipsychotics or other mood stabilizers within 72 hours and antidepressants within 5 days prior to randomization;
  10. Treatment with fluoxetine within one month;
  11. A history of non-response or hypersensitivity to quetiapine or topiramate;
  12. Serious suicidal ideation (> 3 on the CDRS-R89 suicide item, or any serious suicide attempt within the prior 60 days as judged by the investigator; 3=has thoughts about suicide or hurting themselves usually when angry);
  13. Treatment for substance use during 30 days prior to screening (excluding peer support groups);
  14. Court-ordered to substance use treatment;
  15. Acute intoxication;
  16. History of a medication change during the prior 30 days that may have precipitated manic symptoms;
  17. History of a partial response (any improvement) to any existing medications as reported by treating clinician, subjects or legal guardian.

Sites / Locations

  • University of Cincinnati Medical Center

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

Quetiapine and Placebo

Quetiapine and Topiramate

Arm Description

Quetiapine and Placebo

Quetiapine and Topiramate

Outcomes

Primary Outcome Measures

Drinks Per Day
Change in self-reported drinks/day (drinks consumed divided by the number of days during that study period).
Drinks Per Drinking Day
Change in drinks/drinking day (number of drinks consumed divided by the number of days during which alcohol was consumed during that study period)
Percentage of Days Abstinent
Change in percent days abstinent (the number of non-drinking days divided by the number of days in that study period).
Percent Heavy Drinking Days
Change in percent heavy drinking days (number of days of > 4 drinks/day divided by number of days in that study period).

Secondary Outcome Measures

Full Information

First Posted
October 25, 2007
Last Updated
April 21, 2017
Sponsor
University of Cincinnati
Collaborators
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
search

1. Study Identification

Unique Protocol Identification Number
NCT00550394
Brief Title
Efficacy and Tolerability of Topiramate in Treatment of Bipolar Mania and Alcohol Use in Adolescents and Young Adults
Official Title
Quetiapine Plus Topiramate or Placebo for Bipolar Mania & Alcohol Use in Adolescents & Young Adults
Study Type
Interventional

2. Study Status

Record Verification Date
October 2014
Overall Recruitment Status
Completed
Study Start Date
April 2008 (undefined)
Primary Completion Date
June 2010 (Actual)
Study Completion Date
June 2010 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Cincinnati
Collaborators
National Institute on Alcohol Abuse and Alcoholism (NIAAA)

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this research study is to study the effects (both good and bad) of combining quetiapine and topiramate for treating symptoms of bipolar mania (an illness with periods of elation, excessive excitement, irritability, high energy, racing thoughts, poor sleep, poor judgment, reckless behavior) and to study the effects (both good and bad) of combining quetiapine and topiramate for reducing use of alcohol.
Detailed Description
Specific Aim 1: To collect preliminary data regarding the efficacy and tolerability of topiramate for the treatment of alcohol use disorders (alcohol abuse and dependence) in adolescents with bipolar disorder. Hypothesis 1: We hypothesize that topiramate in combination with quetiapine will lead to greater reduction in alcohol consumption (number of drinks per day, number of drinks per drinking day, and number of heavy drinking days) and greater abstinence (percentage of days abstinent) compared with quetiapine alone. Specific Aim 2: To obtain preliminary data regarding the efficacy of topiramate for reducing manic symptoms in adolescents with co-occurring alcohol use and bipolar disorders. Hypothesis 2: We hypothesize that the topiramate in combination with quetiapine will produce greater reduction in Young Mania Rating Scale (YMRS) scores than quetiapine alone.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Bipolar Disorder, Alcohol Abuse
Keywords
Adolescents

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
56 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Quetiapine and Placebo
Arm Type
Active Comparator
Arm Description
Quetiapine and Placebo
Arm Title
Quetiapine and Topiramate
Arm Type
Experimental
Arm Description
Quetiapine and Topiramate
Intervention Type
Drug
Intervention Name(s)
quetiapine and placebo
Other Intervention Name(s)
Quetiapine
Intervention Description
Dosing Schedule and Titration of Quetiapine: open-label quetiapine beginning day 1 at 100 mg/day titrated to 400 mg/day by the end of week 1 Dosing Schedule and Titration of Topiramate: All subjects will be randomized to topiramate or matching placebo which will be administered in a double-blind manner. Topiramate/Placebo titrated from 25 mg twice daily to 150 mg bid by week 4.
Intervention Type
Drug
Intervention Name(s)
Quetiapine and Topiramate
Other Intervention Name(s)
Topiramate
Intervention Description
Dosing Schedule and Titration of Quetiapine: open-label quetiapine beginning day 1 at 100 mg/day titrated to 400 mg/day by the end of week 1 Dosing Schedule and Titration of Topiramate: All subjects will be randomized to topiramate or matching placebo which will be administered in a double-blind manner. Topiramate/Placebo titrated from 25 mg twice daily to 150 mg bid by week 4.
Primary Outcome Measure Information:
Title
Drinks Per Day
Description
Change in self-reported drinks/day (drinks consumed divided by the number of days during that study period).
Time Frame
baseline to 12 weeks or endpoint (up to 11 weeks)
Title
Drinks Per Drinking Day
Description
Change in drinks/drinking day (number of drinks consumed divided by the number of days during which alcohol was consumed during that study period)
Time Frame
baseline to 12 weeks or endpoint (up to 11 weeks)
Title
Percentage of Days Abstinent
Description
Change in percent days abstinent (the number of non-drinking days divided by the number of days in that study period).
Time Frame
baseline to 12 weeks or endpoint (up to 11 weeks)
Title
Percent Heavy Drinking Days
Description
Change in percent heavy drinking days (number of days of > 4 drinks/day divided by number of days in that study period).
Time Frame
baseline to 12 weeks or endpoint (up to 11 weeks)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
12 Years
Maximum Age & Unit of Time
25 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Ages 12-25 years; DSM-IV-TR83 criteria for bipolar disorder, type I, manic or mixed episode; Young Mania Rating Scale (YMRS)86-88 score of > 16 at screening and baseline visits; DSM-IV-TR83 criteria for current alcohol abuse or dependence; Drinking >8 drinks in 30 days within the previous 6 months while meeting DSM-IV criteria for alcohol abuse or dependence. One standard drink is defined as 0.35 liters of beer, 0.15 liters of wine, or 0.04 liters of 80-proof liquor; Fluent in English; Provision of written informed consent/assent; 8) If female and of child bearing potential, agrees to use one of the following method of birth control: complete abstinence, barrier (diaphragm or condom), or oral contraceptive containing > 35 micrograms of ethinyl estradiol (because concomitant use of topiramate and lower estrogen oral contraceptives may lead to contraceptive failure). Exclusion Criteria: Manic symptoms resulting from acute medical illness or acute intoxication or withdrawal from drugs or alcohol as determined by medical evaluation and rapid symptom resolution; Clinically significant alcohol or drug withdrawal symptoms that have the potential to cause serious consequences as determined by vital signs, the CIWA-Ar,84 and medical evaluation; Any unstable medical illness or laboratory abnormalities > 3 times upper limits of normal; A documented history of mental retardation or an IQ total score < 70 as determined by the Wechsler Abbreviated Scale of Intelligence (WASI),154 administered by a trained psychometrician; Any substance use other than alcohol, nicotine, or cannabis during the 30 days prior to study participation; A positive urine pregnancy test or lactating; History of nephrolithiasis. Treatment with concurrent mood stabilizers, antipsychotics or antidepressants; Treatment with antipsychotics or other mood stabilizers within 72 hours and antidepressants within 5 days prior to randomization; Treatment with fluoxetine within one month; A history of non-response or hypersensitivity to quetiapine or topiramate; Serious suicidal ideation (> 3 on the CDRS-R89 suicide item, or any serious suicide attempt within the prior 60 days as judged by the investigator; 3=has thoughts about suicide or hurting themselves usually when angry); Treatment for substance use during 30 days prior to screening (excluding peer support groups); Court-ordered to substance use treatment; Acute intoxication; History of a medication change during the prior 30 days that may have precipitated manic symptoms; History of a partial response (any improvement) to any existing medications as reported by treating clinician, subjects or legal guardian.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Melissa P DelBello, MD
Organizational Affiliation
University of Cincinnati
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Cincinnati Medical Center
City
Cincinnati
State/Province
Ohio
ZIP/Postal Code
45227
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Efficacy and Tolerability of Topiramate in Treatment of Bipolar Mania and Alcohol Use in Adolescents and Young Adults

We'll reach out to this number within 24 hrs